Dose‐dependent prednisolone kinetics
Description
<jats:p>Kinetic data for prednisolone and prednisone have been determined following oral administration of prednisolone over a dosage range of 5 to 200 mg in 43 subjects. Intravenous studies have been performed at 20 mg and 100 mg in 3 subjects. At all dosage levels the elimination t½β for prednisolone remained constant (t½β 3.5 ± 0.2 hr [20 mg], t½β 3.7 ± 0.1 hr [100 mg] mean ± SEM). For prednisolone, there was a linear relationship between dose and AUC<jats:sub>0→∞</jats:sub> and C<jats:sub>max</jats:sub> up to a dose of 20 mg, but above this level AUC0<jats:sub>0→∞</jats:sub> and C<jats:sub>max</jats:sub> demonstrated a less rapid increase as the dose increased. The prednisone AUC<jats:sub>0→∞</jats:sub>. remained a constant proportion, 26 ± 2%, of the prednisolone AUC<jats:sub>0→∞</jats:sub> at all dosage levels. Bioavailability of prednisolone was 98.5 ± 4%. There was a constant amount of prednisolone bound to cortisol‐binding globulin (CBG) (145 ± 16 ng/ml) and as a proportion of the remaining serum prednisolone, the free remained at 14 ±2% and non‐CBG protein‐bound prednisolone at 86 ± 2% over the whole dosage range. The intravenous studies demonstrated a significant difference in the volume of distribution of prednisolone as the dose changed from 20 mg (V<jats:sub>d</jats:sub> 58 ±4 L) to 100 mg (V<jats:sub>d</jats:sub> 90 ± 6 L). Since it has been demonstrated that bioavailability, serum protein binding, prednisone‐prednisolone interconversion, and t½β remained constant over this dosage range, the altered V<jats:sub>d</jats:sub> may account for the nonlinear relationship between AUC and dose.</jats:p>
Journal
-
- Clinical Pharmacology & Therapeutics
-
Clinical Pharmacology & Therapeutics 25 (5part1), 571-578, 1979-05
Wiley
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1363951793207555456
-
- ISSN
- 15326535
- 00099236
-
- Data Source
-
- Crossref